immunotherapies
Feb 02, 2021
Horizon, Viela Deal; Concert Schizo Drug Flop; Gilead Deals with Arcus and Gritstone
Horizon Therapeutics Bolsters its Rare Disease Portfolio in a $3B Viela Bio Buyout Horizon Therapeutics has announced to acquire Viela Bio for about $3.1 billion to augment its portfolio and pipeline of treatments for rare diseases. The shares of Viela Bio skyrocketed more than 52% in premarket trading after the...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
